Abstract |
COX-2 and its product PGE2 enhance carcinogenesis and tumor progression, which has been previously reported in melanoma. As most COX inhibitors cause much toxicity, the downstream microsomal PGE2 synthase-1 (mPGES1) is a consideration for targeting. Human melanoma TMAs were employed for testing mPGES1 protein staining intensity and percentage levels, and both increased with clinical stage; employing a different Stage III TMA, mPGES1 intensity (not percentage) associated with reduced patient survival. Our results further show that iNOS was also highly expressed in melanoma tissues with high mPGES1 levels, and iNOS-mediated NO promoted mPGES1 expression and PGE2 production. An mPGES1-specific inhibitor ( CAY10526) as well as siRNA attenuated cell survival and increased apoptosis. CAY10526 significantly suppressed tumor growth and increased apoptosis in melanoma xenografts. Our findings support the value of a prognostic and predictive role for mPGES1, and suggest targeting this molecule in the PGE2 pathway as another avenue toward improving melanoma therapy.
|
Authors | Sun-Hee Kim, Yuuri Hashimoto, Sung-Nam Cho, Jason Roszik, Denái R Milton, Fulya Dal, Sangwon F Kim, David G Menter, Peiying Yang, Suhendan Ekmekcioglu, Elizabeth A Grimm |
Journal | Pigment cell & melanoma research
(Pigment Cell Melanoma Res)
Vol. 29
Issue 3
Pg. 297-308
(May 2016)
ISSN: 1755-148X [Electronic] England |
PMID | 26801201
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Nitric Oxide Donors
- Nitric Oxide Synthase Type II
- Prostaglandin-E Synthases
- Dinoprostone
|
Topics |
- Animals
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Dinoprostone
(metabolism)
- Disease Progression
- Disease-Free Survival
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Melanoma
(enzymology, pathology)
- Mice, Nude
- Microsomes
(drug effects, enzymology)
- Middle Aged
- Nitric Oxide Donors
(pharmacology)
- Nitric Oxide Synthase Type II
(metabolism)
- Prostaglandin-E Synthases
(genetics, metabolism)
- Signal Transduction
(drug effects)
- Xenograft Model Antitumor Assays
|